News

GRP Hires Mitchel Allen-Rivera as new Executive Vice President of Business Development

The Greater Richmond Partnership (“GRP”), the lead regional economic development organization serving the City of Richmond and counties of Chesterfield, Hanover and Henrico in Virginia, announces that Mitchel Allen-Rivera is the new Executive Vice President of Business Development.

“I am thrilled to welcome Mitchel to Greater Richmond to lead business development,” said Jennifer Wakefield, President and CEO of the Greater Richmond Partnership. “He is a rockstar economic development professional with a stellar reputation and has repeatedly been recognized among the best in the industry.”

Allen-Rivera is relocating to Greater Richmond, Va., from Phoenix, Ariz., where he has worked as the Senior Vice President of Business Development for the Greater Phoenix Economic Council (GPEC) for nearly a decade in roles of increasing responsibility. In addition to his time at GPEC, he worked at the local level in the City of Chandler, Ariz., and as a manager in the financial services industry.

“I am truly honored to be joining such an exceptional team of professionals under Jennifer Wakefield’s leadership,” said Allen-Rivera. “Richmond is an amazing community full of talent and I am eager to contribute to the region’s future development.”

Allen-Rivera has a bachelor’s degree in communication from Arizona State University and is currently pursuing a master of business administration (MBA) from the University of Denver. He has been recognized twice among the Top 50 economic developers in North America by Consultant Connect, been named as a top 40 under 40 professional in economic development by Development Counsellors International and the International Economic Development Council and as Economic Developer of the Year by the Arizona Association for Economic Development.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business